How the answers frame AbbVie
This snapshot (measured 2026-09-29) covers 250 benchmark questions across ChatGPT, Claude, Gemini, Perplexity and Grok, or 1,250 answers, none of which named a brand. AbbVie was named in 97 of them. By assistant that is Grok 31 of 250, Perplexity 20, ChatGPT 17, Gemini 16 and Claude 13. Johnson & Johnson (192), Pfizer (174) and Merck (158) were named more often in the same set.
The contexts were mixed. In ChatGPT's answer on which drugmakers have been most criticized for raising prices on older medications, AbbVie was listed first, tied to Humira list-price increases. In Gemini's answer on congressional testimony, AbbVie appeared among the seven companies at a 2019 Senate Finance Committee hearing. Claude's answers on patient assistance programs listed AbbVie, including for cancer patients. Gemini and Perplexity, asked about the record of bringing new drugs to market, named AbbVie alongside Eli Lilly and others. Perplexity gave it strong launch value, and Gemini described it as pivoting after Humira's patent expiry.
By question intent, visibility was highest on leadership (28%) and employer (17%) questions. It was 12% on pricing transparency and 10% on coverage and access. It was 0% on value, service and safety, and 2% on clinical outcomes. The credit tags attached to AbbVie were thin: five were coded "Not Substantive", two "Financial Performance" and one "Price & Value". The answers named AbbVie often as a list entry rather than crediting it for a distinct quality.
…especially for repeated list-price hikes on **Humira**, a long-established drug.
What the press is saying
PeakMetrics' news index shows 11,245 mentions of AbbVie over the last 30 days, 2,362 with the brand in the headline. That is less volume than Merck (20,731), Eli Lilly (19,681), Amgen (20,317) or Pfizer (19,027) in the same index.
The recent headlines lean toward the investor and deal story. They cover institutional stake disclosures, a stock forecast that mentions the Apogee acquisition, and an IPO plan for AbbVie-allied ADARx with three drugs in the clinic. A separate thread covers UChicago Medicine completing the construction phase of the AbbVie Foundation Cancer Pavilion.
AbbVie's Patient Assistance Program provides free AbbVie medications (including Lupron Depot) to cancer patients with financial need who have limited or no health insurance coverage and live in the United States.
The gap
The press story is financial and institutional, with a philanthropic building project alongside. The AI story, in the answers sampled, is about drug prices, congressional scrutiny, patient assistance eligibility and pipeline productivity. Only the acquisition angle overlaps at all: Grok included AbbVie in its answer on healthcare consolidation, though it led with UnitedHealth Group.
The cancer pavilion headlines and the investor headlines do not appear in the sampled answers. The Humira pricing framing in the ChatGPT answer does not appear in the recent headlines supplied. Volume in the news index does not translate into a matching share of AI answers here: Merck and Amgen have roughly twice AbbVie's news volume, but Amgen was named in fewer answers (69) and Merck in more (158).
5 approvals in the comparison, but strong launch value, including from Rinvoq and Skyrizi.
What to watch
A comms team would note where AbbVie's name is placed. In this snapshot the pricing-criticism list, the congressional testimony list and the patient assistance list are the contexts where it appears, and the sources behind them are what the assistants cite. The zero-visibility intents (value, service, safety) are questions where the answers named other companies instead.
These are single runs of live answers and vary between runs, so the figures are a starting point for repeat benchmarking, not a ranking. The useful next step is to test whether the pricing and access framing persists across repeated runs, and which cited domains carry it.